1. Home
  2. ACB vs AKBA Comparison

ACB vs AKBA Comparison

Compare ACB & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aurora Cannabis Inc.

ACB

Aurora Cannabis Inc.

SELL

Current Price

$4.35

Market Cap

232.3M

Sector

Health Care

ML Signal

SELL

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$0.79

Market Cap

248.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACB
AKBA
Founded
2013
2007
Country
Canada
United States
Employees
N/A
N/A
Industry
Pharmaceuticals and Biotechnology
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
232.3M
248.3M
IPO Year
2016
2014

Fundamental Metrics

Financial Performance
Metric
ACB
AKBA
Price
$4.35
$0.79
Analyst Decision
Buy
Buy
Analyst Count
4
6
Target Price
★ $4.22
$3.92
AVG Volume (30 Days)
1.0M
★ 6.0M
Earning Date
11-04-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 93.94
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$8.09
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.56
$0.81
52 Week High
$6.36
$3.19

Technical Indicators

Market Signals
Indicator
ACB
AKBA
Relative Strength Index (RSI) 60.36 35.17
Support Level $4.08 N/A
Resistance Level $4.49 $0.98
Average True Range (ATR) 0.16 0.04
MACD 0.02 -0.01
Stochastic Oscillator 63.74 11.57

Price Performance

Historical Comparison
ACB
AKBA

About ACB Aurora Cannabis Inc.

Aurora Cannabis Inc is focused on the production, distribution, and sale of cannabis products in Canada and internationally. The Company conducts the production, distribution, and sale of medical cannabis products and, on a very limited basis, consumer cannabis products in Canada pursuant to the Cannabis Act; the production and distribution of wholesale medical cannabis in the European Union pursuant to the German Medicinal Products Act and German Narcotic Drugs Act; and the distribution of wholesale medical cannabis in various international markets, including Australia and New Zealand. Its segments are Canadian Cannabis CGU, European Cannabis CGU, Australia Cannabis CGU, and New Zealand Cannabis CGU, with Canada generating majority revenue.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

Share on Social Networks: